<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2023.1112021</article-id><article-id pub-id-type="publisher-id">JBM-129909</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Effect of Pre-Existing Chronic Medical Conditions on Clinical Features and Disease Outcomes of COVID-19 Infection in Jordanian Children
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Katrel-Nada</surname><given-names>AlAlawneh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ruaa</surname><given-names>Ibrahim</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Qasim</surname><given-names>Mhaidat</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohammad</surname><given-names>Suliman</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ahmad</surname><given-names>Rababah</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hajar</surname><given-names>Ayasreh</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eyad</surname><given-names>Altamimi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan</addr-line></aff><aff id="aff1"><addr-line>Department of Pediatric, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>12</month><year>2023</year></pub-date><volume>11</volume><issue>12</issue><fpage>275</fpage><lpage>286</lpage><history><date date-type="received"><day>5,</day>	<month>November</month>	<year>2023</year></date><date date-type="rev-recd"><day>18,</day>	<month>December</month>	<year>2023</year>	</date><date date-type="accepted"><day>21,</day>	<month>December</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: The COVID-19 pandemic emerged unexpectedly, impacting millions worldwide and, though waning in many regions, remains a significant concern. This study focused on understanding COVID-19’s clinical presentation, disease progression, and outcomes among hospitalized pediatric patients. Additionally, it sought to investigate the impact of concurrent chronic medical conditions on disease severity. 
  Methods: Conducted retrospectively between September 2020 and December 2021, this study observed pediatric patients (below 18 years) hospitalized with confirmed COVID-19 at an Irbid, Jordan tertiary healthcare center. Patients meeting inclusion criteria, including a positive nasal swab PCR test and hospitalization need, were analyzed. Epidemiological and clinical data were collected and segregated into two groups (A and B) based on the presence of chronic conditions. Comparative analysis encompassed presentation, disease trajectory, and outcomes between these groups. 
  Results: Among 451 tested positive patients, 112 were included in the study. Significant differences emerged between the two pediatric groups hospitalized for COVID-19. Those with concurrent chronic illnesses exhibited heightened symptom severity—fever, dyspnea, fatigue—and a higher incidence of abnormal chest radiographs, often requiring intensive care and experiencing elevated mortality rates. 
  Conclusion: This study underscores the criticality of prioritizing COVID-19 management strategies for pediatric patients with pre-existing chronic medical conditions. The findings highlight the increased vulnerability and poorer outcomes experienced by this subgroup, emphasizing the necessity for tailored interventions and focused care approaches.
 
</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd> Pediatric</kwd><kwd> Chronic Disease</kwd><kwd> Disease Severity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Towards the end of 2019 in Wuhan, China, a novel coronavirus was identified and determined to be responsible for the sudden appearance of a cluster of pneumonia infections that initially defied diagnosis and treatment. Subsequently, it spread regionally and then, globally at a rapid pace, thereby resulting in a worldwide pandemic; the World Health Organization named it coronavirus disease 2019 (COVID-19) and declared COVID-19 a pandemic on March 11, 2020 [<xref ref-type="bibr" rid="scirp.129909-ref1">1</xref>] .</p><p>The pandemic caused a global health emergency that lasted more than two years and posed risks and challenging demands on health services worldwide [<xref ref-type="bibr" rid="scirp.129909-ref2">2</xref>] . The disease is caused by the zoonotic coronavirus SARS-CoV-2 and is primarily transmitted from person-to-person via airborne droplets [<xref ref-type="bibr" rid="scirp.129909-ref3">3</xref>] and possibly via other means [<xref ref-type="bibr" rid="scirp.129909-ref4">4</xref>] .</p><p>In early 2020, a survey of the data from different hospitals worldwide reported that children admitted with positive test results accounted for a small percentage of the infected population [<xref ref-type="bibr" rid="scirp.129909-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref7">7</xref>] and mostly did not require increased level of hospitalization compared to that of adults [<xref ref-type="bibr" rid="scirp.129909-ref8">8</xref>] . Furthermore, they rarely required a pediatric intensive care unit admission [<xref ref-type="bibr" rid="scirp.129909-ref9">9</xref>] , although severe cases have been reported [<xref ref-type="bibr" rid="scirp.129909-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref11">11</xref>] .</p><p>Typical symptoms in infected children included fever and cough, while laboratory findings included normal white blood cell and lymphocyte counts [<xref ref-type="bibr" rid="scirp.129909-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref12">12</xref>] ; in pediatric patients, abnormal leukopenia/Lymphopenia and elevated creatinine kinase levels were observed [<xref ref-type="bibr" rid="scirp.129909-ref13">13</xref>] . However, the disease course in children is not always mild, and in some cases, serious complications, such as multisystem inflammatory syndrome, were observed [<xref ref-type="bibr" rid="scirp.129909-ref14">14</xref>] .</p><p>Chronic diseases, including diabetes, hypertension, malignancies, chronic obstructive pulmonary disease, and cardiovascular diseases, in COVID-19 patients can lead to complications and an increased risk of severity and mortality [<xref ref-type="bibr" rid="scirp.129909-ref15">15</xref>] . The increased risk of fatality due to COVID-19 is presumed to be high in patients with cancer as a result of the underlying malignancy [<xref ref-type="bibr" rid="scirp.129909-ref16">16</xref>] . Furthermore, increased mortality was found to be significantly associated with old age, multiple comorbidities, need for intensive care unit (ICU) support, and elevated D-dimer, lactate dehydrogenase, and lactate levels in multivariate analysis [<xref ref-type="bibr" rid="scirp.129909-ref16">16</xref>] .</p><p>A higher risk of severe SARS-CoV-2 infection appears to be associated with older age and a higher number of comorbidities [<xref ref-type="bibr" rid="scirp.129909-ref17">17</xref>] . Various strategies used for managing cases of infected children include ICU admission; other interventions include administration of aspirin, steroids, aspirin, and anticoagulants [<xref ref-type="bibr" rid="scirp.129909-ref18">18</xref>] .</p><p>Data from our part of the world on this important topic is extremely limited. This study aimed to describe the clinical presentation, course, and outcomes of all children with SARS-CoV-2 infection who required hospitalization in our hospital. Furthermore, we aimed to evaluate the effect of coexisting chronic medical conditions on disease severity and outcome. This will influence the management of children with chronic medical illnesses whether infected or at risk of acquiring SARS-CoV-2 infection.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2_1"><title>2.1. Study Setting</title><p>A retrospective cohort study was conducted involving confirmed pediatric cases of COVID-19 infection admitted to King Abdullah University Hospital (KAUH) between September 2020 and December 2021. The study encompassed all consecutive cases of individuals under 18 years of age admitted to KAUH during this period.</p><p>King Abdullah University Hospital (KAUH) stands as the largest referral hospital in Northern Jordan and played a pivotal role in receiving the majority of COVID-19 cases in this region during the pandemic. The Ministry of Health formulated clinical protocols for COVID-19 case management, which were implemented nationwide and regularly updated based on evolving evidence.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>The study included confirmed pediatric cases of COVID-19 diagnosed through real-time reverse transcriptase-polymerase chain reaction (RT-PCR) testing upon hospital admission. Patients older than 18 years, those testing positive solely through the COVID-19 Rapid Antigen Test, individuals not requiring hospitalization, and those lacking sufficient patient data were excluded from the study.</p></sec><sec id="s2_3"><title>2.3. Chronic Disease Definition</title><p>Pediatric chronic disease diagnoses were established by physicians utilizing valid methodologies, professional standards, and diagnostic classification criteria.</p></sec><sec id="s2_4"><title>2.4. COVID-19 Testing</title><p>Trained pediatric residents collected nasopharyngeal swabs, promptly transferring samples to the Serology lab for assessment of SARS-CoV-2 RNA presence. A one-step real-time RT-PCR method utilizing the Molaccu COVID-19 Detection kit manufactured by Zybio Inc., China, was employed in this study.</p></sec><sec id="s2_5"><title>2.5. Severity Score</title><p>Severity assessment relied on clinical notes indicating severe respiratory distress, multi-organ failure, shock development, or the need for ICU admission.</p></sec><sec id="s2_6"><title>2.6. Data Collection</title><p>Patient data were retrieved from electronic records, manually reviewed, and recorded in an Excel sheet. Information encompassed patient demographics, clinical data (chronic diseases, presentation, physical findings, medications, hospitalization details, and outcomes), laboratory measurements, and imaging results (CXR/Chest CT scan). Patients were categorized into two groups: Group A (patients diagnosed with a chronic disease) and Group B (previously healthy patients before COVID-19 symptoms onset), facilitating comparative analysis.</p></sec><sec id="s2_7"><title>2.7. Ethical Approval</title><p>The study received approval from the Institutional Review Board of Jordan University of Science and Technology and the research committee of the Faculty of Medicine (20220143).</p></sec><sec id="s2_8"><title>2.8. Statistical Analysis</title><p>Data analysis utilized IBM SPSS version 23. Descriptive statistics included mean standard deviation (SD) for quantitative data and frequencies/percentages for qualitative data. A significance level of p &lt; 0.05 indicated statistical significance. Bivariate analysis comparing patient characteristics, radiological findings, comorbidities, and laboratory parameters between groups with and without chronic medical illnesses employed nonparametric (Mann–Whitney U test) or parametric tests (Student’s t-test) for continuous variables, as appropriate.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Study Population</title><p>Out of 451 COVID-19 positive cases identified during the study, 112 met the inclusion criteria. The cohort comprised 54.5% females, with a mean presentation age of 11 years (range: 0 - 18).</p></sec><sec id="s3_2"><title>3.2. Chronic Diseases and Demographics</title><p>The cohort was categorized into Group A (patients with chronic diseases, n = 38) and Group B (previously healthy, n = 74). Neurological disorders (26.3%), hematology/oncology (23.7%), and gastrointestinal diseases (21.1%) were the most prevalent chronic conditions. Immunosuppressants (23.6%) were the most commonly used medications among patients with chronic diseases (see <xref ref-type="table" rid="table1">Table 1</xref>).</p></sec><sec id="s3_3"><title>3.3. Symptoms and Disease Presentation</title><p>Group A predominantly showed cough, fever, and fatigue, while Group B exhibited more nasal symptoms, headache, and sore throat. Statistically significant differences were observed; Group A reported fever, dyspnea, and fatigue more frequently (p = 0.02, 0.024, 0.037, respectively), while sore throat was more common in Group B (p = 0.049). Loss of smell or taste was not reported by any patient (see <xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The number of patients with chronic illness and requiring chronic medications</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Distribution of chronic illness</th><th align="center" valign="middle" >Numbers of patients</th></tr></thead><tr><td align="center" valign="middle" >Respiratory</td><td align="center" valign="middle" >5 asthma, 1 chronic lung disease, 1 chronic sinusitis</td></tr><tr><td align="center" valign="middle" >Gastrointestional</td><td align="center" valign="middle" >7 faliure to thrive, 1 lover cirrhosis, 1 auto immune hepatitis</td></tr><tr><td align="center" valign="middle" >Neurological</td><td align="center" valign="middle" >7 developmental delay, 3 epilepsy</td></tr><tr><td align="center" valign="middle" >Hematology/oncology</td><td align="center" valign="middle" >5 malignancy, 2 solid tumors, 1 Idiopathic thrombocytopenia purpura</td></tr><tr><td align="center" valign="middle" >Renal</td><td align="center" valign="middle" >1 nephrotic syndrome, 1 renal failure</td></tr><tr><td align="center" valign="middle" >Cardiac</td><td align="center" valign="middle" >1 patients</td></tr><tr><td align="center" valign="middle" >Endocrine</td><td align="center" valign="middle" >2 diabetes, 1 thyroid disease</td></tr><tr><td align="center" valign="middle" >Chronic medications</td><td align="center" valign="middle" >Numbers of patients</td></tr><tr><td align="center" valign="middle" >Steroids</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Chemotherapy</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Proton pump inhibitors</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Immunomodulators</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison between patients admitted for COVID-19 infection with chronic illnesses and without chronic illness</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Patients admitted with COVID-19 infection with chronic disease (38.34%) (Group A)</th><th align="center" valign="middle" >Patients admitted with COVID-19 infection without chronic disease (74.66%) (Group B)</th><th align="center" valign="middle" >p-Value</th></tr></thead><tr><td align="center" valign="middle" >Average age at diagnosis</td><td align="center" valign="middle" >7.7 &#177; 5.6</td><td align="center" valign="middle" >10.5 &#177; 5.9</td><td align="center" valign="middle" >0.017</td></tr><tr><td align="center" valign="middle" >Gender (M %)</td><td align="center" valign="middle" >53%</td><td align="center" valign="middle" >45%</td><td align="center" valign="middle" >0.423</td></tr><tr><td align="center" valign="middle" >Symptomatic (n, %)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Cough</td><td align="center" valign="middle" >15 (39.5)</td><td align="center" valign="middle" >17 (23.0)</td><td align="center" valign="middle" >0.070</td></tr><tr><td align="center" valign="middle" >- Fever</td><td align="center" valign="middle" >15 (39.5)</td><td align="center" valign="middle" >14 (18.9)</td><td align="center" valign="middle" >0.020</td></tr><tr><td align="center" valign="middle" >- Fatigue</td><td align="center" valign="middle" >10 (26.3)</td><td align="center" valign="middle" >8 (10.8)</td><td align="center" valign="middle" >0.037</td></tr><tr><td align="center" valign="middle" >- Nasal symptoms</td><td align="center" valign="middle" >5 (13.2)</td><td align="center" valign="middle" >12 (16.2)</td><td align="center" valign="middle" >0.676</td></tr><tr><td align="center" valign="middle" >- Dyspnea</td><td align="center" valign="middle" >9 (23.7)</td><td align="center" valign="middle" >6 (8.1)</td><td align="center" valign="middle" >0.024</td></tr><tr><td align="center" valign="middle" >- Headache</td><td align="center" valign="middle" >2 (5.3)</td><td align="center" valign="middle" >11 (14.9)</td><td align="center" valign="middle" >0.758</td></tr><tr><td align="center" valign="middle" >- Sore throat</td><td align="center" valign="middle" >1 (2.6)</td><td align="center" valign="middle" >11 (14.9)</td><td align="center" valign="middle" >0.049</td></tr><tr><td align="center" valign="middle" >- Vomiting</td><td align="center" valign="middle" >1 (2.6)</td><td align="center" valign="middle" >8 (10.8)</td><td align="center" valign="middle" >0.133</td></tr><tr><td align="center" valign="middle" >- Others (tachycardia, chest pain, unsteady gait)</td><td align="center" valign="middle" >3 (7.9)</td><td align="center" valign="middle" >5 (6.8)</td><td align="center" valign="middle" >0.831</td></tr><tr><td align="center" valign="middle" >- Muscle aches</td><td align="center" valign="middle" >5 (13.2)</td><td align="center" valign="middle" >3 (4.1)</td><td align="center" valign="middle" >0.080</td></tr><tr><td align="center" valign="middle" >- Tachypnea</td><td align="center" valign="middle" >3 (7.9)</td><td align="center" valign="middle" >4 (5.4)</td><td align="center" valign="middle" >0.606</td></tr><tr><td align="center" valign="middle" >- Abdominal pain</td><td align="center" valign="middle" >2 (5.3)</td><td align="center" valign="middle" >5 (6.8)</td><td align="center" valign="middle" >0.758</td></tr><tr><td align="center" valign="middle" >- Diarrhea</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5 (6.8)</td><td align="center" valign="middle" >0.103</td></tr><tr><td align="center" valign="middle" >- Poor appetite</td><td align="center" valign="middle" >3 (7.9)</td><td align="center" valign="middle" >1 (1.3)</td><td align="center" valign="middle" >0.076</td></tr><tr><td align="center" valign="middle" >- Hypoactivity</td><td align="center" valign="middle" >2 (5.3)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.048</td></tr><tr><td align="center" valign="middle" >- Loss of smell</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Loss of taste</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Radiological evaluation:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Abnormal CXR (n, %)</td><td align="center" valign="middle" >14 (36.8)</td><td align="center" valign="middle" >13 (17.6)</td><td align="center" valign="middle" >0.027</td></tr><tr><td align="center" valign="middle" >Laboratory evaluation:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- High inflammatory markers (ESR, CRP)</td><td align="center" valign="middle" >5 (13.2)</td><td align="center" valign="middle" >12 (16.2)</td><td align="center" valign="middle" >0.676</td></tr><tr><td align="center" valign="middle" >- Average LDH</td><td align="center" valign="middle" >560</td><td align="center" valign="middle" >417</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Average Ferritin</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >32.1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Hb (Avg &#177; SD)</td><td align="center" valign="middle" >12.2 &#177; 1.80</td><td align="center" valign="middle" >12.6 &#177; 1.67</td><td align="center" valign="middle" >0.353</td></tr><tr><td align="center" valign="middle" >- WBC</td><td align="center" valign="middle" >8634.6 &#177; 5947.04</td><td align="center" valign="middle" >7622 &#177; 2972</td><td align="center" valign="middle" >0.327</td></tr><tr><td align="center" valign="middle" >- Lymphocyte count</td><td align="center" valign="middle" >3039.69 &#177; 3410.97</td><td align="center" valign="middle" >2447.84 &#177; 1234.4</td><td align="center" valign="middle" >0.286</td></tr><tr><td align="center" valign="middle" >- Neutrophilic count</td><td align="center" valign="middle" >4284.49 &#177; 3025.9</td><td align="center" valign="middle" >3820.3 &#177; 2138.27</td><td align="center" valign="middle" >0.454</td></tr><tr><td align="center" valign="middle" >- Platelet count</td><td align="center" valign="middle" >270,807 &#177; 202832.5</td><td align="center" valign="middle" >279145.8 &#177; 149500.4</td><td align="center" valign="middle" >0.844</td></tr><tr><td align="center" valign="middle" >Level of care:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Floor</td><td align="center" valign="middle" >33 (86.8)</td><td align="center" valign="middle" >71 (95.9)</td><td align="center" valign="middle" >0.080</td></tr><tr><td align="center" valign="middle" >- ICU</td><td align="center" valign="middle" >5 (13.2)</td><td align="center" valign="middle" >3 (4.1)</td><td align="center" valign="middle" >0.080</td></tr><tr><td align="center" valign="middle" >Highest respiratory support:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- None</td><td align="center" valign="middle" >32 (84.2)</td><td align="center" valign="middle" >73 (98.6)</td><td align="center" valign="middle" >0.036</td></tr><tr><td align="center" valign="middle" >- CPAP</td><td align="center" valign="middle" >2 (5.3)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.048</td></tr><tr><td align="center" valign="middle" >- HFNC</td><td align="center" valign="middle" >1 (2.6)</td><td align="center" valign="middle" >1 (1.4)</td><td align="center" valign="middle" >0.652</td></tr><tr><td align="center" valign="middle" >- Mechanical ventilation</td><td align="center" valign="middle" >3 (7.9)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.016</td></tr><tr><td align="center" valign="middle" >COVID-19 specific treatment:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Hydroxychloroquine</td><td align="center" valign="middle" >1 (2.6)</td><td align="center" valign="middle" >8 (10.8)</td><td align="center" valign="middle" >0.133</td></tr><tr><td align="center" valign="middle" >- Steroids</td><td align="center" valign="middle" >5 (13.2)</td><td align="center" valign="middle" >3 (4.1)</td><td align="center" valign="middle" >0.080</td></tr><tr><td align="center" valign="middle" >- IVIG</td><td align="center" valign="middle" >1 (2.6)</td><td align="center" valign="middle" >1 (1.4)</td><td align="center" valign="middle" >0.653</td></tr><tr><td align="center" valign="middle" >- Remdesivir</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1 (1.4)</td><td align="center" valign="middle" >0.465</td></tr><tr><td align="center" valign="middle" >- Azithromycin</td><td align="center" valign="middle" >1 (2.6)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.166</td></tr><tr><td align="center" valign="middle" >Outcome:</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >- Death</td><td align="center" valign="middle" >5 (13.2)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.002</td></tr></tbody></table></table-wrap></sec><sec id="s3_4"><title>3.4. Laboratory and Radiographic Findings</title><p>No significant differences were noted in inflammatory markers, white blood cell counts, hemoglobin, or platelet counts between the two groups. Abnormal chest radiographs were more prevalent in Group A (36.8%) compared to Group B (17.6%) (p = 0.027) (see <xref ref-type="table" rid="table2">Table 2</xref>).</p></sec><sec id="s3_5"><title>3.5. Hospitalization and Intensive Care</title><p>Group A showed a higher ICU admission rate (13.2%) than Group B (4.1%). A subset of Group A patients required respiratory support, with no significant difference in treatment protocols between the groups. However, mortality was significantly higher in Group A (13.2%) compared to Group B (p = 0.02) (see <xref ref-type="table" rid="table2">Table 2</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Our study focused on understanding the influence of pre-existing chronic medical conditions on the clinical features and outcomes of COVID-19 in pediatric patients. Similar to earlier investigations [<xref ref-type="bibr" rid="scirp.129909-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref22">22</xref>] , our study categorizing patients into Groups A and B showed distinct clinical presentations and outcomes.</p><p>A study on a cohort of 41 infected Chinese individuals found a death rate of 15%, a rate of ICU admission of 32%, and 32% had underlying diseases [<xref ref-type="bibr" rid="scirp.129909-ref19">19</xref>] . Our study revealed a similar percentage for chronic conditions (34%), and the death rate is also close to our data (13.2%) for Group A patients; however, ICU admission percentages were different from our findings, which were 13.2% and 4.1% for Groups A and B, respectively.</p><p>Studies have shown that the disease in children is generally milder than that in adults, although severe cases with multi-organ involvement have been reported [<xref ref-type="bibr" rid="scirp.129909-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref22">22</xref>] .</p><p>A study on 1,320,488 cases in the United States in 2020 found equal incidence rates of COVID-19 among males and females and the lowest incidence for children in the age group ≤ 9 years, but the symptoms and their severity varied with age, sex, and underlying conditions, with severe symptoms (with a high rate of hospitalization) for males and older patients [<xref ref-type="bibr" rid="scirp.129909-ref20">20</xref>] . This finding is consistent with those of earlier studies.</p><p>As of May 30, 2020, the following underlying health conditions were found to be most prevalent among COVID-19 patients in the US: cardiovascular disease (32%), diabetes (30%), and chronic lung disease (18%). Patients with these conditions are six times more likely to require hospitalization and 12 times more likely to die than those with no underlying conditions [<xref ref-type="bibr" rid="scirp.129909-ref20">20</xref>] , which is similar to the results obtained in our study. Other studies have estimated the prevalence of underlying conditions among COVID-19 patients [<xref ref-type="bibr" rid="scirp.129909-ref23">23</xref>] .</p><p>A study in the US found that, between March 2020 and May 2021, 3106 children infected with COVID-19 were hospitalized, with ~9% suffering a severe respiratory form of the disease. They also reported associations between severity and feeding tube dependence and diabetes mellitus and obesity for the 2 - 17 years age group of hospitalized children [<xref ref-type="bibr" rid="scirp.129909-ref24">24</xref>] , which is consistent with our results. Another study found an increased prevalence of underlying medical conditions among COVID-19 hospitalized patients, and older adults have increased probability of hospitalization [<xref ref-type="bibr" rid="scirp.129909-ref25">25</xref>] .</p><p>A study, performed in early 2020, on 72,314 cases in China found a low incidence of COVID-19 (&lt;1%) among young children (&lt;10 years old) [<xref ref-type="bibr" rid="scirp.129909-ref6">6</xref>] . Another study, performed in 2020 in China, on 1391 children reported an incidence rate of 12.3%, and the median age of the infected children was 6.7 years, with 15.8% of the infected children showing no symptoms or radiological evidence of infection and 41.5% presenting fever [<xref ref-type="bibr" rid="scirp.129909-ref26">26</xref>] . In this study, the incidences of fever in the two groups were 39.5% and 18.9%, respectively. The incidence of fever is generally less common among previously healthy children, although the aforementioned study did not elaborate on the percentage of infected children with underlying medical conditions. A meta-study on 9335 children from 31 countries found that the mean incidence rate of asymptomatic children was 13% and those with fever or cough was 63% and 34%, respectively [<xref ref-type="bibr" rid="scirp.129909-ref20">20</xref>] . The latter value is close to the data obtained for group A patients in this study. A study in 2021 reviewed results of 129 studies that analyzed data from 10,251 young patients (with a mean age of seven) from 31 countries and found that 57.4% required hospitalization (96 of whom died) and 88.9% recovered. The most prevalent among the diverse symptoms were fever and cough 63.3% and 33.7%, respectively [<xref ref-type="bibr" rid="scirp.129909-ref27">27</xref>] . The latter is consistent with the results obtained for both the groups in this study. Our observations align with prior studies [<xref ref-type="bibr" rid="scirp.129909-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref23">23</xref>] highlighting the severity of COVID-19 among children with underlying chronic diseases, emphasizing increased mortality rates and ICU admissions in these cohorts</p><p>A study in 2021 found diabetes patients to be at a high risk of increased severity and worse outcomes, including increased mortality, need for respiratory intervention, and ICU admissions, although they did not have an increased risk of infection [<xref ref-type="bibr" rid="scirp.129909-ref28">28</xref>] . Additionally, another study found that these patients were at a high risk of severity, complications, and death and three times more likely to need critical respiratory intervention [<xref ref-type="bibr" rid="scirp.129909-ref28">28</xref>] . This finding is consistent with our finding that Group A patients were three times more likely to require ICU admission.</p><p>Diabetes mellitus is associated with increased disease severity and a high risk of mortality in patients with COVID-19 [<xref ref-type="bibr" rid="scirp.129909-ref29">29</xref>] . Additionally, our findings are supported by another study on early COVID-19 patient data that demonstrated an increased incidence among patients with underlying chronic medical conditions, including obesity, diabetes, chronic respiratory, kidney, and cardiovascular disease [<xref ref-type="bibr" rid="scirp.129909-ref30">30</xref>] .</p><p>Another study revealed that COVID-19 patients suffering from chronic respiratory diseases were at a high risk of mortality [<xref ref-type="bibr" rid="scirp.129909-ref31">31</xref>] . A study on 50 German patients with and without (26 and 24, respectively) acute respiratory distress syndrome also found an association between the severity of COVID-19 and elevated inflammation and pre-existing respiratory diseases and obesity [<xref ref-type="bibr" rid="scirp.129909-ref32">32</xref>] . This result is in qualitative agreement with our findings. An incidence of one or more underlying conditions, including asthma and obesity, was found in over one quarter of the 43,465 young (≤18 years) patients included in the study, and a high risk for severity associated with them was observed [<xref ref-type="bibr" rid="scirp.129909-ref33">33</xref>] .</p><p>Other studies, found a high risk of severity, mortality, and ICU admission among COVID-19 patients with chronic diseases, including hypertension [<xref ref-type="bibr" rid="scirp.129909-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref35">35</xref>] . Consistent with existing literature [<xref ref-type="bibr" rid="scirp.129909-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref26">26</xref>] , our findings emphasize the heightened risk of severity, complications, and mortality in pediatric COVID-19 patients with specific chronic medical conditions, such as diabetes, chronic respiratory diseases, and obesity.</p><p>A literature review of 29 studies on chest computerized tomography images of 1026 children infected with COVID-19 found lower incidence and severity of abnormal lesions in children than those in adults, with the percentages of normal and abnormal scans at ~35.7% and ~27.7%, respectively [<xref ref-type="bibr" rid="scirp.129909-ref36">36</xref>] . In this study, the overall incidence of abnormal chest scans was 24.1%, which is similar to the aforementioned value of 27.7% reported in a previous study. Our study’s concordance with previous research [<xref ref-type="bibr" rid="scirp.129909-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref36">36</xref>] showcasing the association between abnormal chest scans and disease severity in pediatric COVID-19 cases underscores the importance of imaging in evaluating disease progression.</p><p>Our results Highlighting the necessity for tailored strategies and prioritized vaccination efforts [<xref ref-type="bibr" rid="scirp.129909-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.129909-ref30">30</xref>] , our findings stress the need to protect children with underlying chronic illnesses due to their increased vulnerability to severe outcomes.</p></sec><sec id="s5"><title>5. Study Limitations</title><p>Acknowledging the limitations of our study, including the short study period and potential data entry errors, we propose a larger-scale, multicenter prospective study to validate and expand upon these findings, emphasizing the necessity for prolonged follow-up and enhanced sample size calculations for conclusive results.</p></sec><sec id="s6"><title>6. Conclusion</title><p>In summary, our study contributes to the existing body of knowledge by reaffirming the impact of pre-existing chronic medical conditions on the severity and outcomes of COVID-19 in pediatric patients. These insights underscore the imperative of tailored clinical management and prioritized vaccination strategies for this vulnerable population.</p></sec><sec id="s7"><title>Acknowledgements</title><p>None.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors have no conflict of interest to disclose.</p></sec><sec id="s9"><title>Ethical Statement</title><p>The study was approved by the ethical committee/IRB and scientific committee at Jordan University of Science and Technology and granted the no. 20220143.</p></sec><sec id="s10"><title>Cite this paper</title><p>AlAlawneh, K.-N., Ibrahim, R., Mhaidat, Q., Suliman, M., Rababah, A., Ayasreh, H. and Altamimi, E. (2023) Effect of Pre-Existing Chronic Medical Conditions on Clinical Features and Disease Outcomes of COVID-19 Infection in Jordanian Children. Journal of Biosciences and Medicines, 11, 275-286. https://doi.org/10.4236/jbm.2023.1112021</p></sec><sec id="s11"><title>Abbreviations</title><p>COVID-19: Coronavirus disease 2019; ICU: Intensive Care Unit.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.129909-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cucinotta, D. and Vanelli, M. (2020) WHO Declares COVID-19 a Pandemic. Acta Biomedica, 91, 157-160.</mixed-citation></ref><ref id="scirp.129909-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Shao, J., Wang, C. and Li, W. (2020) The Epidemiology and Therapeutic Options for the COVID-19. Precision Clinical Medicine, 3, 71–84. https://doi.org/10.1093/pcmedi/pbaa017</mixed-citation></ref><ref id="scirp.129909-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chhikara, B.S., Rathi, B., Singh, J. and Poonam, F.N.U. (2020) Corona virus SARS-CoV-2 Disease COVID-19: Infection, Prevention and Clinical Advances of the Prospective Chemical Drug Therapeutics. Chemical Biology Letters, 7, 63-72.</mixed-citation></ref><ref id="scirp.129909-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X. and Shan, H. (2020) Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology, 158, 1831-1833.e3. https://doi.org/10.1002/rmv.2146</mixed-citation></ref><ref id="scirp.129909-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">CDC COVID-19 Response Team (2020) Coronavirus Disease 2019 in Children—United States, February 12-April 2, 2020. Morbidity and Mortality Weekly Report, 69, 422-426. https://doi.org/10.15585/mmwr.mm6914e4</mixed-citation></ref><ref id="scirp.129909-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Z. and McGoogan, J.M. (2020) Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA, 323, 1239-1242. https://doi.org/10.1001/jama.2020.2648</mixed-citation></ref><ref id="scirp.129909-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Korean Society of Infectious Diseases (2020) Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020. Journal of Korean Medical Science, 35, e112. https://doi.org/10.3346/jkms.2020.35.e112</mixed-citation></ref><ref id="scirp.129909-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bai, K., Liu, W., Liu, C., Fu, Y., Hu, J., Qin, Y., Li, C., et al. (2020) Clinical Analysis of 25 COVID-19 Infections in Children. The Pediatric Infectious Disease Journal, 39, e100-e103. https://doi.org/10.1097/INF.0000000000002740</mixed-citation></ref><ref id="scirp.129909-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Esposito, S., Caramelli, F. And Principi, N. (2021) What Are the Risk Factors for Admission to the Pediatric Intensive Unit among Pediatric Patients with COVID-19? Italian Journal of Pediatrics, 47, Article No. 103. https://doi.org/10.1186/s13052-021-01057-w</mixed-citation></ref><ref id="scirp.129909-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nikolopoulou, G.B. and Maltezou, H.C. (2022) COVID-19 in Children: Where Do We Stand? Archives of Medical Research, 53, 1-8. https://doi.org/10.1016/j.arcmed.2021.07.002</mixed-citation></ref><ref id="scirp.129909-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gkoutzourelas, A., Bogdanos, D.P. and Sakkas, L.I. (2020) Kawasaki Disease and COVID-19. Mediterranean Journal of Rheumatology, 31, 268-274. https://doi.org/10.31138/mjr.31.3.268</mixed-citation></ref><ref id="scirp.129909-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ho, C.L.T., Oligbu, P., Ojubolamo, O., Pervaiz, M. and Oligbu, G. (2020) Clinical Characteristics of Children with COVID-19. AIMS Public Health, 7, 258-273. https://doi.org/10.3934/publichealth.2020022</mixed-citation></ref><ref id="scirp.129909-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ding, Y., Yan, H. and Guo, W. (2020) Clinical Characteristics of Children with COVID-19: A Meta-Analysis. Frontiers in Pediatrics, 8, Article 431. https://doi.org/10.3389/fped.2020.00431</mixed-citation></ref><ref id="scirp.129909-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Godfred-Cato, S., Bryant, B., Leung, J., Oster, M.E., Conklin, L., Abrams, J., et al. (2020) COVID-19—Associated Multisystem Inflammatory Syndrome in Children—United States, March-July 2020. Morbidity and Mortality Weekly Report, 69, 1074-1080. https://doi.org/10.15585/mmwr.mm6932e2</mixed-citation></ref><ref id="scirp.129909-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ssentongo, P., Ssentongo, A.E., Heilbrunn, E.S., Ba, D.M. and Chinchilli, V.M. (2020) Association of Cardiovascular Disease and 10 Other Pre-Existing Comorbidities with COVID-19 Mortality: A Systematic Review and Meta-Analysis. PLOS ONE, 15, e0238215. https://doi.org/10.1371/journal.pone.0238215</mixed-citation></ref><ref id="scirp.129909-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuna-Villaorduna, A., Verma, A., et al. (2020) Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discovery, 10, 935-941. https://doi.org/10.1158/2159-8290.CD-20-0516</mixed-citation></ref><ref id="scirp.129909-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Maltezou, H.C., Raftopoulos, V., Vorou, R., Papadima, K., Mellou, K., Spanakis, N., Tsakris, A., et al. (2021) Association between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients with SARS-CoV-2 Infection. The Journal of Infectious Diseases, 223, 1132-1138. https://doi.org/10.1093/infdis/jiaa804</mixed-citation></ref><ref id="scirp.129909-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Adeyinka, A., Bailey, K., Pierre, L. and Kondamudi, N. (2021) COVID 19 Infection: Pediatric Perspectives. Journal of the American College of Emergency Physicians Open, 2, e12375. https://doi.org/10.1002/emp2.12375</mixed-citation></ref><ref id="scirp.129909-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Cao, B., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5</mixed-citation></ref><ref id="scirp.129909-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Cui, Y., Tian, M., Huang, D., Wang, X., Huang, Y., Fan, L., Wang, L., Chen, Y., Liu, W., Zhang, K., et al. (2020) A 55-Day-Old Female Infant Infected with COVID 19: Presenting with Pneumonia, Liver Injury, and Heart Damage. The Journal of Infectious Diseases, 221, 1775-1781. https://doi.org/10.1093/infdis/jiaa113</mixed-citation></ref><ref id="scirp.129909-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Chmielewska, B., Barratt, I., Townsend, R., Kalafat, E., van der Meulen, J., Gurol-Urganci, I., Khalil, A., et al. (2021) Effects of the COVID-19 Pandemic on Maternal and Perinatal Outcomes: A Systematic Review and Meta-Analysis. The Lancet Global Health, 9, E759-E772. https://doi.org/10.1016/S2214-109X(21)00079-6</mixed-citation></ref><ref id="scirp.129909-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Dong, Y., Mo, X.I., Hu, Y., Qi, X., Jiang, F., Jiang, Z. and Tong, S. (2020) Epidemiological Characteristics of 2143 Pediatric Patients with 2019 Coronavirus Disease in China. Pediatrics, 145, e20200702. https://doi.org/10.1542/peds.2020-0702</mixed-citation></ref><ref id="scirp.129909-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chow, N., Fleming-Dutra, K., Gierke, R., et al. (2020) Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions among Patients with Coronavirus Disease 2019—United States, February 12-March 28, 2020. Morbidity and Mortality Weekly Report, 69, 382-386. https://doi.org/10.15585/mmwr.mm6913e2</mixed-citation></ref><ref id="scirp.129909-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Woodruff, R.C., Campbell, A.P., Taylor, C.A., Chai, S.J., Kawasaki, B., Meek, J., et al. (2022) Risk Factors for Severe COVID-19 in Children. Pediatrics, 149, e2021053418. https://doi.org/10.1542/peds.2021-053418</mixed-citation></ref><ref id="scirp.129909-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Garg, S., Kim, L., Whitaker, M., et al. (2020) Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1-30, 2020. Morbidity and Mortality Weekly Report, 69, 458-464. https://doi.org/10.15585/mmwr.mm6915e3</mixed-citation></ref><ref id="scirp.129909-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lu, X., Zhang, L., Du, H., Zhang, J., Li, Y.Y., Qu, J., Wong, G.W., et al. (2020) SARS-CoV-2 Infection in Children. New England Journal of Medicine, 382, 1663-1665. https://doi.org/10.1056/NEJMc2005073</mixed-citation></ref><ref id="scirp.129909-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Irfan, O., Muttalib, F., Tang, K., Jiang, L., Lassi, Z.S. and Bhutta, Z. (2021) Clinical Characteristics, Treatment and Outcomes of Paediatric COVID-19: A Systematic Review and Meta-Analysis. Archives of Disease in Childhood, 106, 440-448. https://doi.org/10.1136/archdischild-2020-321385</mixed-citation></ref><ref id="scirp.129909-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Unnikrishnan, R. and Misra, A. (2021) Diabetes and COVID19: A Bidirectional Relationship. Nutrition &amp; Diabetes, 11, Article No. 21. https://doi.org/10.1038/s41387-021-00163-2</mixed-citation></ref><ref id="scirp.129909-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Cui, Y., Shen, M., Zhang, J., Liu, B., Dai, M., Pan, P., et al. (2020) Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study. Diabetes Research and Clinical Practice, 165, Article ID: 108227. https://doi.org/10.1016/j.diabres.2020.108227</mixed-citation></ref><ref id="scirp.129909-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Guan, W.J., Liang, W.H., Zhao, Y., Liang, H.R., Chen, Z.S., Li, Y.M., He, J.X., et al. (2020) Comorbidity and Its Impact on 1590 Patients with COVID-19 in China: A Nationwide Analysis. European Respiratory Journal, 55, Article ID: 2000547. https://doi.org/10.1183/13993003.00547-2020</mixed-citation></ref><ref id="scirp.129909-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Morand, A., Fabre, A., Minodier, P., Boutin, A., Vanel, N., Bosdure, E. and Fournier, P.E. (2020) COVID-19 Virus and Children: What Do We Know? Archives de Pediatrie, 27, 117-118. https://doi.org/10.1016/j.arcped.2020.03.001</mixed-citation></ref><ref id="scirp.129909-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Dreher, M., Kersten, A., Bickenbach, J., Balfanz, P., Hartmann, B., Cornelissen, C., Marx, N., et al. (2020) The Characteristics of 50 Hospitalized COVID-19 Patients with and without ARDS. Deutsches Arzteblatt International, 117, 271-278. https://doi.org/10.3238/arztebl.2020.0271</mixed-citation></ref><ref id="scirp.129909-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Kompaniyets, L., Agathis, N.T., Nelson, J.M., Preston, L.E., Ko, J.Y., Belay, B., Goodman, A.B., et al. (2021) Underlying Medical Conditions Associated with Severe COVID-19 Illness among Children. JAMA Network Open, 4, e2111182. https://doi.org/10.1001/jamanetworkopen.2021.11182</mixed-citation></ref><ref id="scirp.129909-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Geng, J., Yu, X., Bao, H., Feng, Z., Yuan, X., Zhang, J., Yu, H., et al. (2021) Chronic Diseases as a Predictor for Severity and Mortality of COVID-19: A Systematic Review with Cumulative Meta-Analysis. Frontiers in Medicine, 1442, Article 588013. https://doi.org/10.3389/fmed.2021.588013</mixed-citation></ref><ref id="scirp.129909-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Clark, C.E., McDonagh, S.T., McManus, R.J. and Martin, U. (2021) COVID-19 and Hypertension: Risks and Management. A Scientific Statement on Behalf of the British and Irish Hypertension Society. Journal of Human Hypertension, 35, 304-307.https://doi.org/10.1038/s41371-020-00451-x</mixed-citation></ref><ref id="scirp.129909-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Nino, G., Zember, J., Sanchez-Jacob, R., Gutierrez, M.J., Sharma, K. And Linguraru, M.G. (2021) Pediatric Lung Imaging Features of COVID-19: A Systematic Review and Meta-Analysis. Pediatric Pulmonology, 56, 252-263. https://doi.org/10.1002/ppul.25070</mixed-citation></ref></ref-list></back></article>